Drug Database
YE

yellow fever vaccine (Arilvax)

✓ Approved

Novartis AG · 疫苗 · 疫苗

什么是 yellow fever vaccine?

yellow fever vaccine 是一种疫苗,由Novartis AG研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Arilvax
公司Novartis AG
药物类别疫苗, 大分子
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

治疗适应症

yellow fever vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsYellow fever✓ Approved

相关研究文献

PubMedJournal of cosmetic dermatology2026-11-18

Efficacy and Safety of Yellow Light Monotherapy Versus Yellow Light Combined With 20% Vitamin C for the Treatment of Melasma: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Study.

Du Dan D, Liu Xu X, Huang Yuwei Y, Wu Shuwei S et al.

Melasma treatment remains challenging due to limited effective and safe options. This study evaluated the efficacy and safety of yellow light phototherapy alone versus combined with 20% vitamin C in treating melasma. Seventy-one patients were randomly assigned to receive twice-weekly yellow light phototherapy combined with either 20% vitamin C solution (n = 35) or its corresponding vehicle (n = 36). The primary outcome was the change from baseline in modified Melasma Area and Severity Index (mMASI) score. Secondary outcomes consisted of changes relative to baseline in Physician Global Assessment (PGA), Subjective Satisfaction Assessment (SA), melanin index (MI), individual typology angle (ITA°), transepidermal water loss (TEWL), skin hydration content (SCH), skin pore and skin texture parameters. At Week 12, the combination group exhibited significantly greater reductions in mMASI scores (-1.95 ± 2.11 vs. -0.69 ± 2.19, p = 0.027) and lower Physician Global Assessment (PGA) scores (4.48 ± 0.80 vs. 5.06 ± 0.54, p = 0.002) compared with the monotherapy group. The combination group exhibited a more remarkable decrease in melanin index (MI) (-13.07, 95% CI: -17.82, -8.32 vs. -3.16, 95% CI: -7.86, 1.54, p = 0.005) and a more prominent elevation in individual typology angle (ITA°) (6.23, 95% CI: 4.38, 8.08 vs. 1.23, 95% CI: -0.60, 3.05) (p < 0.001). Moreover, significant improvements in skin pore status and skin texture were noted in the combination group (p < 0.05). No statistically significant between-group differences were found in transepidermal water loss (TEWL) and skin hydration (SCH). No adverse events occurred throughout the trial. The participant treatment satisfaction rate reached 60.00% in the combination group, which was significantly higher than 22.55% in the control group. Combined 20% vitamin C plus yellow light phototherapy yielded statistically superior melasma improvements relative to yellow light monotherapy, though the absolute reduction in mMASI was modest. The combination regimen preserved skin barrier function and exhibited good tolerability.

PMID 43047232
阅读全文 →
PubMedNature immunology2026-11-18

Fever-induced OR560 promotes antibacterial immunity through macrophage pseudopod formation and phagocytosis.

Cai Hong H, Yi Jun-Xi JX, Sun Jing-Yi JY, Li Jin J et al.

Fever is a conserved physiological response to pathogen infection. However, how fever promotes host defense remains poorly understood. Here we find that fever empowers antibacterial immunity by inducing olfactory receptor 560 (OR560) to promote macrophage phagocytosis. Through a genome-wide CRISPR screen, we discovered that OR560 is indispensable for macrophage phagocytosis. Febrile temperature drives the serum response factor-dependent OR560 induction in macrophages to boost phagocytosis. OR560 responds to bacteria-derived peptides and plays an essential role in mediating pseudopod formation-a key step required for target uptake. Modulation of body temperature in mice showed that the immune-amplifying effect of fever depends predominantly on OR560. We further demonstrated that the genetic ablation of either Olfr560 or serum response factor (Srf) in mice not only abolished fever-potentiated macrophage phagocytosis but also led to catastrophic defects in bacterial clearance and increased mortality upon infections. Thus, our work reveals that OR560 is a pivotal regulator of fever-enhanced antibacterial phagocytosis and integrates both pathogen-derived and febrile signals to ensure a robust response to infection.

PMID 43045751
阅读全文 →
PubMedJournal of nanobiotechnology2026-11-18

Baculovirus-based production of virus-like particles for avian influenza: development, immunogenicity, and cross-protection against H5 and H7 AIVs.

He Yanjuan Y, Dong Yajing Y, Kong Dexin D, Chen Huixin H et al.

The persistent threat of H5 and H7 highly pathogenic avian influenza (HPAI) necessitates effective broad-spectrum vaccines. This study systematically evaluated the immunogenicity and protective efficacy of H5N6 virus-like particle (H5N6-VLP) vaccine and subsequently developed a trivalent VLP vaccine (H5N6-H5N8-H7N9-VLP) using the baculovirus expression system (BEVS). Production of H5N6-VLP was optimized at a multiplicity of infection (MOI) of 0.1 to achieve efficient assembly. The H5N6-VLP vaccine induced potent immune responses in specific-pathogen-free (SPF) chickens, providing 100% protection against homologous H5N6-GD154 virus when the HA titer reached 9 log2. Compared with traditional inactivated vaccines, the H5N6-VLP vaccine induced faster humoral immune responses and higher CD8⁺ T cell proportions. The HI seroconversion rate was 30% on day 7 post-immunization (0% for inactivated vaccine), reached 100% by day 10, while it was only 80% on day 14 for the inactivated vaccine. Furthermore, the protective efficacy of the H5N6-VLP vaccine was associated with increased IFN‑γ expression and elevated proportions of B cells and CD8⁺ T cells. Although both vaccines provided complete homologous protection, the H5N6-VLP vaccine showed better cross-protection against the heterologous H5N1-D889 strain (70% vs. 40%). A delayed challenge experiment further demonstrated that the H5N6-VLP vaccine induced durable immunity, with HI titers remaining above the protective threshold and 100% protection against homologous challenge at 8 weeks post-immunization. Based on these findings, a trivalent H5N6-H5N8-H7N9-VLP vaccine was developed. The trivalent vaccine induced substantial antibody responses and provided complete protection against parental and circulating strains, with efficacy comparable to a commercial inactivated vaccine and no detectable antigenic interference between components. Our findings highlight the potential of the BEVS-derived H5N6-VLP vaccine, particularly its early antibody induction, which allows rapid flock protection during acute HPAI outbreaks, and its cross-reactivity against heterologous strains. Furthermore, the trivalent vaccine formulation extends the potential application of this VLP platform for broad-spectrum HPAI control.

PMID 43046102
阅读全文 →
PubMedBioinformatics and biology insights2026-11-18

Formulation of a Novel NS5A- and NS5B-Based Chimeric Vaccine Against Hepatitis C Virus: An Artificial Intelligence-Supported Approach.

Niknam Maryam M, Zohrabzadeh Maryam M, Hahashempour Ava A, Honari Jahromi Ali A et al.

We aimed to design a multiepitope vaccine against hepatitis C virus (HCV) with the potential to elicit broad protective immunity against diverse HCV genotypes through computational design.Method: One hundred sequences of the most widespread subtypes of HCV were retrieved from the Los Alamos National Laboratory database, and consensus sequences of the NS5A and NS5B proteins were generated to construct an efficient vaccine for human use. Numerous B-cell lymphocyte, cytotoxic T-lymphocyte and helper T-lymphocyte epitopes located in the conserved domains of HCV proteins and similar in human and mouse alleles were evaluated criteria for use in the vaccine construct. Population coverage analysis identified that substantial parts of the worldwide population carry epitopes and their corresponding alleles within their genome, which confirms that the vaccine candidate is an effective agent against this lethal disease. Codon optimization and in silico cloning of eukaryotic and prokaryotic vectors validated the strong expression of the vaccine construct in the host systems. Molecular docking analysis revealed favorable binding affinities between the vaccine construct and toll-like receptors, which confirmed the vaccine's capacity to induce robust and stable immune responses against the hepatitis C virus. We incorporated new bioinformatic methods to design multiepitope vaccine against HCV. The development of a vaccine targeting multi genotypes of HCV could potentially provide for long-term protection against infection and may mitigate the risk of drug resistance across various genotypes and subtypes. Current research emphasizes the need for a vaccine that can elicit comprehensive immune responses, including both neutralizing antibodies and T-cell responses, to effectively address the genetic diversity of the virus. Future experimental studies are essential to validate predicted immunogenicity, structural stability, and protective efficacy before clinical consideration.

PMID 43047676
阅读全文 →
PubMedWomen's health reports (New Rochelle, N.Y.)2026-11-18

Postpartum HPV vaccination uptake: attitudes, beliefs, and determinants of acceptance.

Currier Jessica J JJ, Gagliuso Amelia H AH, Myers Emily E, Nguyen Christine Gt CG et al.

High-risk human Papillomavirus (hrHPV) is associated with six cancers. Although vaccination rates in the United States are increasing, series completion remains below the Healthy People 2030 goal of 80%. Pregnant individuals are a population with low HPV vaccination coverage, with only 7.5%-15.5% of patients aged 18-26 years receiving HPV vaccination prior to delivery. The postpartum period represents an opportunity to initiate or complete the HPV vaccination series. This study examined knowledge, attitudes, and beliefs regarding HPV vaccination among previously unvaccinated postpartum individuals and compared perspectives between those who accepted and declined vaccination. Postpartum individuals aged 18-26 were offered HPV vaccination. Participants completed a survey and semi-structured interviews. Patient characteristics, including HPV knowledge, were compared between participants who accepted and declined vaccination. Qualitative thematic analysis identified factors influencing vaccine attitudes and beliefs. Among participants, 53% accepted HPV vaccination and 46% declined. HPV knowledge was lower among participants who accepted the vaccine compared to those who declined; although this difference was not statistically significant. Vaccine hesitancy was associated with concerns regarding safety, effectiveness, and the need for additional information. Qualitative findings indicated that belief in the vaccine's cancer prevention benefits facilitated vaccine acceptance. Frequent healthcare encounters during the perinatal period created opportunities for provider counseling and vaccine delivery. The perinatal period offers a critical opportunity to promote HPV vaccination through frequent health care encounters and opportunities for ongoing education. However, access alone may be insufficient to optimize vaccine uptake. Vaccine hesitancy remained a significant barrier, and the immediate postpartum period was not consistently perceived as an optimal time for vaccination among some individuals experiencing heightened stress or competing medical priorities. Strategies to increase postpartum HPV vaccination should prioritize strong provider recommendations, clear communication about the vaccine's cancer prevention benefits, and interventions that addres vaccine hesitancy and structural barriers to vaccination.

PMID 43048345
阅读全文 →
PubMedClinical nephrology2026-11-18

Renal involvement in familial Mediterranean fever: A unique case of C3 glomerulopathy.

Morkoç Berna B, Yalçın Funda F, Arslan Yekta Can YC, Çakır Çağlar Ç et al.

PMID 43049285
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多yellow fever vaccine